Core Insights - Klotho Neurosciences plans to acquire assets from Turn Biotechnologies, focusing on longevity therapeutics and cellular reprogramming [1][2] - The acquisition includes Turn's Epigenetic Reprogramming of Age (ERA) platform and the eTurna RNA delivery system, developed at Stanford University [2] - The deal is contingent upon due diligence, a definitive agreement, and typical closing conditions [1] Technology and Applications - The technologies aim to restore tissue function and rejuvenate somatic cells, with potential applications in ophthalmology, dermatology, osteoarthritis, muscle health, immunology, and amyotrophic lateral sclerosis (ALS) [3] - Klotho's acquisition includes a partnership with a South Korean pharmaceutical company, potentially valued at up to $300 million [3] Strategic Implications - The collaboration highlights commercial interest in Turn's platform and its broad technological potential [4] - Post-acquisition, Klotho plans to rebrand to reflect its expanded mission and therapeutic capabilities [4] - Key personnel from Turn Biotechnologies will join Klotho's management and R&D teams after the transaction [4] Leadership Perspective - Klotho's CEO emphasized the transformative nature of the acquisition, linking the Klotho gene to anti-aging and neuroprotection [5] - The integration of Turn's ERA technology, which utilizes six RNA molecules, aims to enhance cellular rejuvenation capabilities [6]